Post-diagnosis Use of Anti-Inflammatory Meds May Improve Ovarian Cancer-specific Survival, Study Suggests

Post-diagnosis Use of Anti-Inflammatory Meds May Improve Ovarian Cancer-specific Survival, Study Suggests
Regular use of anti-inflammatory medication, such as aspirin, after an ovarian cancer diagnosis appears to improve ovarian cancer-specific survival, a study shows. The study, “Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS/NHSII): a cohort study,” was published in the journal Lancet Oncology. Despite the fact that ovarian cancer is the eighth most common cause of cancer death among women worldwide, there are limited tools for early detection of the disease. In fact, 60 percent of women with ovarian cancer are diagnosed after the disease has already spread to other organs. An increasing number of studies have shown that inflammation leads to worse outcomes in patients with ovarian cancer. As a result, researchers have looked into treating patients with anti-inflammatory medications, such as aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs), as an add-on to standard treatment. However, there is little data available on whether post-diagnosis use of anti-inflammatories leads to improved overall survival in ovarian cancer patients. To address this, researchers investigated whether the use of aspirin, non-aspirin NSAIDs, and paracetamol would lead to improved ovarian cancer-specific survival in women with epithelial ovarian cancer. Using data from the Nurses’ Health Study (NHS) and Nurses’ Health Study II (NHSII), two long-term continuing studies that have each enrolled more than 100,000 nurses in the United States, researchers examined the self-reported regular
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *